Further, the FDA-approved HDAC inhibitor vorinostat has been proposed in combination with small molecule inhibitors of aPKC for treating advanced BCC, since aPKC appears to mediate the recruitment of HDAC1 to GLI1 (Mirza et al., 2017). Here, GLI1 is linked to skin basal cell carcinoma.